Disease · MONDO_0005737

Ebola hemorrhagic fever

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Ebola hemorrhagic fever. Diseases, record MONDO_0005737. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005737

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Ebola hemorrhagic fever; Open Targets
Open Targets ID: MONDO_0005737; Open Targets
Other names: EHF, Ebola, Ebola fever, Ebola virus disease, Ebolavirus caused disease or disorder, Ebolavirus disease or disorder, Ebolavirus infectious disease, Hemorrhagic Fever, Ebola; Open Targets
Disease Ontology: DOID:4325; Disease Ontology
MeSH: D019142; MeSH
NCI Thesaurus: C36171; NCI Thesaurus
Orphanet: ORPHA:319218; Orphanet
Highest stage of its drugs: Approval, for 4 of its 16 drugs, from FDA; Open Targets

Drugs16

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ANSUVIMAB	CHEMBL4594388	Antibody	Approval	FDA	4	2	2	Drugs and targets
ATOLTIVIMAB	CHEMBL4298183	Antibody	Approval	FDA	4	2	1	Drugs and targets
MAFTIVIMAB	CHEMBL4298184	Antibody	Approval	FDA	4	2	1	Drugs and targets
ODESIVIMAB	CHEMBL4298188	Antibody	Approval	FDA	4	2	1	Drugs and targets
COSFROVIXIMAB	CHEMBL3990001	Antibody	Phase 2/3	ClinicalTrials.gov	3	3	3	Drugs and targets
LARCAVIXIMAB	CHEMBL3989980	Antibody	Phase 2/3	ClinicalTrials.gov	3	3	3	Drugs and targets
PORGAVIXIMAB	CHEMBL3989996	Antibody	Phase 2/3	ClinicalTrials.gov	3	3	3	Drugs and targets
AMIODARONE	CHEMBL633	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
REMDESIVIR	CHEMBL4065616	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
FAVIPIRAVIR	CHEMBL221722	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 16

See all 16 drugs

Targets13

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
AGTR1	Type-1 angiotensin II receptor	1	Type-1 angiotensin II receptor antagonist	Phase 1/2	https://conductscience.org/library/genes/185	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	1	Macrophage colony stimulating factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/1436	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Phase 1/2	https://conductscience.org/library/genes/1956	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	1	Tyrosine-protein kinase receptor FLT3 inhibitor	Phase 1/2	https://conductscience.org/library/genes/2322	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/2324	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1	HMG-CoA reductase inhibitor	Phase 1/2	https://conductscience.org/library/genes/3156	Drugs and targets
KCNH2	Voltage-gated inwardly rectifying potassium channel KCNH2	1	HERG blocker	Phase 2/3	https://conductscience.org/library/genes/3757	Drugs and targets
KDR	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/3791	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	1	Stem cell growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/3815	Drugs and targets

1 to 10 of 13

See all 13 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03719586	Investigational Therapeutics for the Treatment of People With Ebola Virus Disease	Phase 2/3	681	2021-09-08	Ebola Virus	ANSUVIMAB, ATOLTIVIMAB, COSFROVIXIMAB, LARCAVIXIMAB, MAFTIVIMAB, ODESIVIMAB, PORGAVIXIMAB, REMDESIVIR	Its record names the disease	ClinicalTrials.gov
NCT02363322	Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection	Phase 1/2	72	2019-05-14	Ebola Virus Infection	COSFROVIXIMAB, LARCAVIXIMAB, PORGAVIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT02380625	Multiple Treatments for Ebola Virus Disease (EVD)	Phase 1/2	150		Ebola Virus Disease	ATORVASTATIN, AZITHROMYCIN, ERLOTINIB, IRBESARTAN, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT02329054	Efficacy of Favipiravir Against Ebola (JIKI)	Phase 2	126		Ebola Virus Disease	FAVIPIRAVIR	Its record names the disease	ClinicalTrials.gov
NCT02662855	Efficacy of Favipiravir Against Severe Ebola Virus Disease	Phase 2	77		Ebola Virus Disease	FAVIPIRAVIR	Its record names the disease	ClinicalTrials.gov
NCT02739477	Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen	Phase 2	2		Ebola Virus Survivor	FAVIPIRAVIR	Its record names the disease	ClinicalTrials.gov
NCT02271347	An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease	Phase 2	0		Ebola Virus	BRINCIDOFOVIR	Its record names the disease	ClinicalTrials.gov
NCT02307591	Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)	Phase 2/3	0		Ebola Virus Disease	AMIODARONE	Its record names the disease	ClinicalTrials.gov
NCT02389192	Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult Volunteers	Phase 1	0		Healthy	COSFROVIXIMAB, LARCAVIXIMAB, PORGAVIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT05067166	Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP				Ebola Virus Disease	ANSUVIMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
B/Current Standard of Care Plus ZMapp vs A/Current Standard of Care Alone: Mortality	8 of 36	13 of 35	71	NCT02363322	Trial comparisons
B/Current Standard of Care Plus ZMapp vs A/Current Standard of Care Alone: deaths from any cause	8 of 36	13 of 35	71	NCT02363322	Trial comparisons
B/Current Standard of Care Plus ZMapp vs A/Current Standard of Care Alone: serious adverse events	11 of 36	13 of 35	71	NCT02363322	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35127447	RESULT	2	PubMed
28231247	RESULT	1	PubMed
27046271	RESULT	1	PubMed
33217357	DERIVED	1	PubMed
31774950	DERIVED	1	PubMed
27732819	DERIVED	1	PubMed
26930627	DERIVED	1	PubMed
26768569	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005737

GET https://conductscience.org/api/diseases/v1/MONDO_0005737/drugs

API reference For AI assistants